Eli Lilly and Company closed on its purchase of a small biotech company, CoLucid Pharmaceuticals, for almost $1 billion last March. Beyond being a truly “big deal,” the CoLucid purchase is also a development that shows the continuing scope and vibrancy of our life sciences community. It is a true “Indiana win” in every sense: for over a decade, CoLucid’s development for commercialization has been accomplished through a major business transaction led by the participating firms in the Indiana Future Fund (IFF), the $73 million venture capital fund-of-funds that BioCrossroads organized in 2003.
Come hear the unique story of how the Lilly molecule was spun out into a separate company, funded by local venture capital, matured outside the state, and brought back to Indiana through Lilly’s acquisition. The story of CoLucid is our “proof of concept” that Indiana is indeed a leader in this 21st Century of medical innovation.
In this session, hosted by Butler University, we’ll hear firsthand from investors and leadership on the journey of a life sciences startup and learn about pivotal decisions that landed the acquisition. Speakers include:
- Darren Carroll, senior vice president, Corporate Business Development, Eli Lilly and Company
- John Barnard, managing director, Pearl Street Venture Funds
- Thomas P. Mathers, former president and CEO, CoLucid Pharmaceuticals, Inc.
- Arthur Pappas, managing partner, Pappas Capital
Parking is available in the Sunset Avenue garage located between 46th & 49th streets just north of Schrott Center.